Does the media favor PVLA or TGTX?

In the previous week, Palvella Therapeutics and Palvella Therapeutics both had 8 articles in the media. Palvella Therapeutics' average media sentiment score of 1.69 beat TG Therapeutics' score of 1.24 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PVLA or APGE more profitable?

Apogee Therapeutics' return on equity of -29.88% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -47.84% -38.33% Apogee Therapeutics N/A -29.88% -28.08%

Does the media favor PVLA or APGE?

In the previous week, Apogee Therapeutics had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 10 mentions for Apogee Therapeutics and 8 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.69 beat Apogee Therapeutics' score of 1.63 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Apogee Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is PVLA or SYRE more profitable?

Spyre Therapeutics' return on equity of -30.74% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -47.84% -38.33% Spyre Therapeutics N/A -30.74% -22.23%

Does the media refer more to PVLA or SYRE?

In the previous week, Spyre Therapeutics had 10 more articles in the media than Palvella Therapeutics. MarketBeat recorded 18 mentions for Spyre Therapeutics and 8 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.69 beat Spyre Therapeutics' score of 0.08 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Spyre Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALKS or PVLA?

In the previous week, Palvella Therapeutics had 1 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Palvella Therapeutics and 7 mentions for Alkermes. Palvella Therapeutics' average media sentiment score of 1.69 beat Alkermes' score of 0.72 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to PVLA or RYTM?

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Palvella Therapeutics. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 8 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.69 beat Rhythm Pharmaceuticals' score of 1.42 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rhythm Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Palvella Therapeutics (PVLA) Competitors

$149.97 -0.36 (-0.24%)

As of 08/28/2026 04:00 PM Eastern

Compare

PVLA vs. TGTX, APGE, SYRE, ALKS, and RYTM

Should you buy Palvella Therapeutics stock or one of its competitors? Palvella Therapeutics's main competitors and comparable companies include TG Therapeutics (TGTX), Apogee Therapeutics (APGE), Spyre Therapeutics (SYRE), Alkermes (ALKS), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Palvella Therapeutics compare to TG Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Palvella Therapeutics currently has a consensus price target of $209.14, indicating a potential upside of 39.46%. TG Therapeutics has a consensus price target of $63.00, indicating a potential upside of 16.82%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Palvella Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

TG Therapeutics has a net margin of 55.22% compared to Palvella Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
TG Therapeutics	55.22%	73.49%	34.14%

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Palvella Therapeutics and Palvella Therapeutics both had 8 articles in the media. Palvella Therapeutics' average media sentiment score of 1.69 beat TG Therapeutics' score of 1.24 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.48	-$41.72M	-$4.83	N/A
TG Therapeutics	$799.54M	10.32	$447.18M	$2.74	19.68

Summary

TG Therapeutics beats Palvella Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Palvella Therapeutics compare to Apogee Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

In the previous week, Apogee Therapeutics had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 10 mentions for Apogee Therapeutics and 8 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.69 beat Apogee Therapeutics' score of 1.63 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Apogee Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Palvella Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Palvella Therapeutics presently has a consensus price target of $209.14, suggesting a potential upside of 39.46%. Apogee Therapeutics has a consensus price target of $126.77, suggesting a potential downside of 6.07%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Palvella Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

Apogee Therapeutics' return on equity of -29.88% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Palvella Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.48	-$41.72M	-$4.83	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Summary

Palvella Therapeutics beats Apogee Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Spyre Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Spyre Therapeutics' return on equity of -30.74% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Spyre Therapeutics	N/A	-30.74%	-22.23%

In the previous week, Spyre Therapeutics had 10 more articles in the media than Palvella Therapeutics. MarketBeat recorded 18 mentions for Spyre Therapeutics and 8 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.69 beat Spyre Therapeutics' score of 0.08 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Spyre Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics presently has a consensus price target of $209.14, indicating a potential upside of 39.46%. Spyre Therapeutics has a consensus price target of $109.69, indicating a potential upside of 21.39%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Palvella Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Palvella Therapeutics has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market.

Palvella Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.48	-$41.72M	-$4.83	N/A
Spyre Therapeutics	$890K	8,928.38	-$155.20M	-$1.95	N/A

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Palvella Therapeutics beats Spyre Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

In the previous week, Palvella Therapeutics had 1 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Palvella Therapeutics and 7 mentions for Alkermes. Palvella Therapeutics' average media sentiment score of 1.69 beat Alkermes' score of 0.72 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alkermes has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

Alkermes currently has a consensus price target of $54.56, indicating a potential upside of 15.09%. Palvella Therapeutics has a consensus price target of $209.14, indicating a potential upside of 39.46%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Palvella Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Alkermes has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.39	$241.66M	$0.38	124.76
Palvella Therapeutics	$42.81M	50.48	-$41.72M	-$4.83	N/A

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alkermes has a net margin of 3.96% compared to Palvella Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Summary

Alkermes beats Palvella Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Palvella Therapeutics (NASDAQ:PVLA) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Palvella Therapeutics. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 8 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.69 beat Rhythm Pharmaceuticals' score of 1.42 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rhythm Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.1% of Palvella Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Palvella Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Palvella Therapeutics' return on equity of -47.84% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Palvella Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.48	-$41.72M	-$4.83	N/A
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A

Palvella Therapeutics currently has a consensus target price of $209.14, suggesting a potential upside of 39.46%. Rhythm Pharmaceuticals has a consensus target price of $141.12, suggesting a potential upside of 31.68%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Palvella Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

Palvella Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Summary

Palvella Therapeutics beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PVLA vs. The Competition

Export

Metric	Palvella Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.16B	$3.93B	$7.20B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-31.05	11.62	273.16	25.45
Price / Sales	50.48	1,357.44	634.19	94.29
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	9.96	16.53	12.98	6.14
Net Income	-$41.72M	-$22.80M	$3.48B	$348.86M
7 Day Performance	5.58%	-0.31%	0.13%	-0.80%
1 Month Performance	-0.15%	9.80%	7.08%	4.13%
1 Year Performance	176.95%	55.66%	24.67%	15.17%

Palvella Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PVLA Palvella Therapeutics	2.5862 of 5 stars	$149.97 -0.2%	$209.14 +39.5%	+177.0%	$2.16B	$42.81M	N/A	N/A	News Coverage Positive News
TGTX TG Therapeutics	3.455 of 5 stars	$55.72 +1.3%	$63.00 +13.1%	+83.9%	$8.53B	$799.54M	20.34	290	Positive News
APGE Apogee Therapeutics	1.6462 of 5 stars	$134.96 +0.0%	$124.43 -7.8%	+271.1%	$8.39B	N/A	N/A	91	News Coverage Positive News
SYRE Spyre Therapeutics	2.31 of 5 stars	$93.61 flat	$109.69 +17.2%	+448.0%	$8.23B	N/A	N/A	73	News Coverage Analyst Forecast
ALKS Alkermes	2.2502 of 5 stars	$48.90 -0.5%	$54.56 +11.6%	+63.7%	$8.20B	$1.48B	128.69	2,050

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PVLA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palvella Therapeutics (PVLA) Competitors

PVLA vs. TGTX, APGE, SYRE, ALKS, and RYTM

How does Palvella Therapeutics compare to TG Therapeutics?

Summary

How does Palvella Therapeutics compare to Apogee Therapeutics?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Summary

How does Palvella Therapeutics compare to Alkermes?

Summary

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palvella Therapeutics (PVLA) Competitors

PVLA vs. TGTX, APGE, SYRE, ALKS, and RYTM

How does Palvella Therapeutics compare to TG Therapeutics?

Do analysts prefer PVLA or TGTX?

Is PVLA or TGTX more profitable?

Do insiders and institutionals believe in PVLA or TGTX?

Does the media favor PVLA or TGTX?

Which has more volatility & risk, PVLA or TGTX?

Which has stronger valuation and earnings, PVLA or TGTX?

Summary

How does Palvella Therapeutics compare to Apogee Therapeutics?

Does the media favor PVLA or APGE?

Which has more risk and volatility, PVLA or APGE?

Do institutionals & insiders have more ownership in PVLA or APGE?

Do analysts prefer PVLA or APGE?

Is PVLA or APGE more profitable?

Which has better earnings and valuation, PVLA or APGE?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Is PVLA or SYRE more profitable?

Does the media refer more to PVLA or SYRE?

Do analysts recommend PVLA or SYRE?

Which has more risk & volatility, PVLA or SYRE?

Which has stronger earnings and valuation, PVLA or SYRE?

Do institutionals & insiders have more ownership in PVLA or SYRE?

Summary

How does Palvella Therapeutics compare to Alkermes?

Does the media favor ALKS or PVLA?

Which has more volatility and risk, ALKS or PVLA?

Do analysts prefer ALKS or PVLA?

Which has better earnings & valuation, ALKS or PVLA?

Do institutionals & insiders believe in ALKS or PVLA?

Is ALKS or PVLA more profitable?

Summary

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Does the media refer more to PVLA or RYTM?

Do institutionals & insiders hold more shares of PVLA or RYTM?

Is PVLA or RYTM more profitable?

Which has better earnings & valuation, PVLA or RYTM?

Do analysts prefer PVLA or RYTM?

Which has more risk & volatility, PVLA or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools